Nanospectra Biosciences

Nanospectra Biosciences is a clinical-stage medical device company developing a novel, focal therapy for cancer using its proprietary AuroLase platform. The technology combines inert gold-silica nanoparticles with a near-infrared laser to achieve precise, incision-free thermal ablation of solid tumors, starting with prostate cancer. This approach aims to offer a targeted treatment with the potential to preserve organ function and reduce side effects compared to standard therapies. The company is advancing its lead program through pivotal clinical studies in the U.S. and has secured Breakthrough Device Designation from the FDA.

AuroLase Therapy: A platform using intravenously administered gold-silica nanoshells (AuroShell particles) that accumulate in tumors and are activated by a near-infrared laser to cause precise, localized thermal ablation.

In prostate cancer focal therapy, Nanospectra competes with established technologies like High-Intensity Focused Ultrasound (HIFU), cryoablation, and photodynamic therapy. Its key differentiator is the use of systemically delivered, activatable nanoparticles for selective targeting. Broader competition includes other novel ablation techniques like irreversible electroporation (Nanoknife) and laser interstitial thermal therapy (LITT).